AstraZeneca Plans To Drug The Undruggable With Scorpion Partnership
Pays $75m Upfront
The UK major will work with the US biotech to develop up to three precision medicines targeting cancer proteins previously thought undruggable via conventional methods.
You may also be interested in...
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
The UK major is paying $30m upfront and up to an extra $730m for the rights to Neurimmune’s NI006, which is in Phase Ib trials for the treatment of transthyretin amyloid cardiomyopathy.
The company is using proceeds from last year’s handover of its lead epilepsy program to Takeda to fuel a push in neurology development.